12533 results for
Refine Your Search
Kathleen Sakamoto
Dr. Kathleen Sakamoto is Professor of Pediatrics at Stanford University School of Medicine. She has been studying the causes of AML and developing new…
Michael Savona
Dr. Savona is the Head of Hematology, Cellular Therapy and Stem Cell Transplant, the Beverly and George Rawlings Director of Hematologic Malignancies …
Marc Seifert
Marc Seifert graduated in Biology at the University of Cologne and did his PhD at the Institute of Cell Biology (IFZ) at the University Hospital Essen…
Mala Shanmugam
I am a cancer biologist and Associate Professor in the Department of Hematology and Medical Oncology at the Winship Cancer Institute, Emory University…
Robert Orlowski
Dr. Robert Orlowski, the Principal Investigator of this proposal, serves as the Florence Maude Thomas Cancer Research Professor and Director of the My…
Stephen Nimer
Dr. Nimer has cared for patients with MDS, AML, multiple myeloma, and lymphoma for over three decades. This melding of clinical studies and care, with…
Grzegorz Nowakowski
Grzegorz (Greg) Nowakowski, M.D., is a consultant and a Professor of Oncology and Medicine, Division of Hematology at Mayo Clinic in Rochester,Minneso…
Developing novel therapeutic approaches for classical and variant hairy cell leukemia
In this proposal, we have combined clinical and research expertise in HCL across Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College…
Testing targeted therapy in LCH
We propose to the hypothesis that patients with LCH who fail initial chemotherapy will respond to a targeted strategy of blocking MAPK signaling throu…
Restoring lymphoma immunosurveillance by combined EZH2 inhibition and immunotherapy
The project builds on evidence that mutations leading to persistent EZH2 activation drive germinal center lymphomagenesis by disrupting surveillance…
Discovery of Aging-Driven Mechanisms Causing Clonal Hematopoiesis (CH) and its Progression to Hematological Malignancy
My research focuses on why and how risk of acute myeloid leukemia (AML) increases with aging. Studying naturally aged mouse models in combination with…
BRAF inhibition as an alternative to chemotherapy in the treatment strategy of hairy cell leukemia
Hairy cell leukemia (HCL) is very sensitive to chemotherapy, whose toxicity to the bone marrow and the immune system is however concerning. We have es…
Precision Medicine Inhibitor and Immunotherapy Approaches for High-Risk Childhood Leukemias
Dr Tasian’s scientific passion is successful development of precision medicine therapies for childhood leukemia. Her translational laboratory researc…
Genetic roadmaps to synthetic lethality in myeloproliferative neoplasms (MPNs)
Myeloproliferative neoplasms (MPNs) carry JAK2(V617F), MPL(W515L) and mutations in calreticulin (CALRmut) often accompanied by mutations in TET2, ASXL…
Improving targeted adoptive cell therapy of myeloma
Dr. Madhav Dhodapkar, M.D., of Winship Cancer Institute of Emory University, Atlanta, leads a , LLS Specialized Center of Research team focused on ad…
A precision-based all-oral combination of venetoclax, oral decitabine, and IDH1/2 targeted inhibition for patients with IDH1 or IDH2 mutated AML
My ultimate goal is to develop more effective, better tolerated, and individualized treatment for patients with AML. This project focuses on AML patie…
Exploiting metabolic dependencies, tumor plasticity and their consequences for drug response of HCL
We have long standing experience in the field of HCL research. The aim of this research proposal is to characterize HCL on single cell level across mu…
Reaching out to underserved & minority patients with hematological diseases in the southeastern US
Cancer Center (VICC) is the only NCI designated cancer center that serves both adult and pediatric populations in TN, one of the highest states in th…
CAR T-cell therapy in central nervous system (CNS) lymphoma: a study in safety and efficacy and a model in which to study mechanisms of neurotoxicity
CAR are highly effective in lymphoma but limited by a profound and potentially fatal toxicity involving the central nervous system (CNS). Little is k…
Therapeutic targeting of AML stem cells
Our SCOR team seeks to fundamentally reinvent the ways in which physicians diagnose and treat acute myeloid leukemia (AML). For over years, AML has b…
T-cell immunotherapy for prevention of COVID-19 following bone marrow transplantation
infections may be prolonged in cancer patients and may enable intrahost development of virulent viral variants. Adoptive immunotherapy with has been…
REACH: Recruitment Expansion through community Access to Clinical trials in Hematologic malignancies
Mayo Clinic Rochester (MCR) is a tertiary center with , blood cancer visits annually. Circa % of patients referred to MCR come from states: MN, WI, I…